Stroke, a cerebrovascular disease with a high mortality rate, is categorized as either ischemic or hemorrhagic. Current existing therapies have limitations, including a narrow time window for treatment. As stroke induces a rapid and large immune response, immune cells and inflammatory mediators have become promising therapeutic targets for both ischemic and hemorrhagic strokes. In recent years, T cells have been investigated for their role in the pathogenesis of secondary injury and their therapeutic potential after stroke. And regulatory T cells, as one of the subpopulations of T cells, have been proved neuroprotective at both acute and recovery stages. In this review, we summarize the existing roles of Tregs in stroke and the various methods available for Treg intervention, and then provide a perspective for the future of immunotherapy in stroke.

Chronic cerebral artery occlusion is an important cause of ischemic stroke, resulting in up to 45% of all ischemic strokes. Therefore, treatment of chronic cerebral artery occlusion is critical to improve outcomes in effected patients. In the past, treatment of chronic cerebral artery occlusion focused on drugs and surgical bypass, but effectiveness and potential benefits are not well-supported. In recent years, endovascular recanalization therapy has become more prominent as a treatment for chronic cerebral artery occlusion, due to advances in endovascular procedures, experience and equipment, as well as more advanced imaging methods. Small clinical studies have shown that interventional therapy for chronic cerebral artery occlusions may be safe and effective, yet, there is still a lack of uniform guidelines. This review discusses the current support for recanalization of chronic intracranial large vessel occlusion.

NCyborg Project, a new stroke rehabilitation pattern based on brain computer interface (BCI) and brain-inspired intelligent robots, is set up by Tongji Hospital and BrainCo. We will briefly introduce this project in this paper.